Apogee Therapeutics, Inc. (APGE) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An external analyst notes that investing in Apogee Therapeutics, Inc.’s common stock entails substantial uncertainty given its clinical-stage status, lack of approved products, and continuing operating losses, which may never translate into profitability or revenue. The company’s dependence on unproven programs such as zumilokibart (APG777) and others heightens the risk that developmental setbacks, competitive pressures, or regulatory hurdles could materially impair future prospects and shareholder value.
The average APGE stock price target is $105.67, implying 49.01% upside potential.
To learn more about Apogee Therapeutics, Inc.’s risk factors, click here.